Adipocytokines as possible etiopathogenetic mechanisms leading to a higher incidence of autoimmune thyroiditis in patients with type 2 diabetes mellitus – enlarged study

Czech version

Authors: Štefan Sotak ¹; Zbynek Schroner ^2,3; Ivica Lazúrová ¹; Ivana Jochmanová ¹; Marek Felš Ci ¹; Darina Petrášová ⁴; Izabela Bertková ⁵; Miriam Mitníková ⁶
Authors‘ workplace: I. interná klinika LF UPJŠ a UNLP Košice ¹; Lekárska fakulta UPJŠ v Košiciach ²; SchronerMED, s. r. o. Košice ³; Laboratórium výskumných biomodelov LF UPJŠ v Košiciach ⁴; Ústav experimentálnej medicíny LF UPJŠ v Košiciach ⁵; Oddelenie laboratórnej medicíny UNLP Košice ⁶
Published in: Diab Obez 2022; 22(43): 44-51
Category:

Overview

Introduction: Autoimmune thyroiditis (AIT) and type 2 diabetes mellitus (T2D) are the most common endocrinological diseases worldwide. Relationship between T1D and AIT is well-known and described. Relation between these diseases explains several hypotheses. One of them is influence of some adipocytokines. Objective: This study evaluated relationship between three adipocytokines (adiponectin, resistin, visfatin) and thyroidal status in patients with T2D and AIT compared to control group (CG). Material and methods: The group consisted of four subgroups: patients with T2D without thyreopathies (n = 80), patients with AIT on substitution therapy without diabetes and prediabetes (n = 54), patients with T2D and AIT on substitution therapy (n = 47) and healthy subjects as a CG (n = 43). We investigated parameters of thyroid and glycid metabolism and levels of three adipocytokines by venous blood-letting. We also measured thyroid gland volume, height, weight and waist. Results: The mean level of resistin in the group of patients with diabetes and thyroiditis was significantly higher than in patients with thyroiditis without diabetes and than in the CG. We found a weak negative correlation between visfatin and fasting glucose levels in patients with thyroiditis without diabetes. We detected a weak negative correlation between resistin and glycated hemoglobin and a weak negative correlation between visfatin and thyroid gland volume in patients with diabetes without thyroiditis. In the CG we determined a weak positive correlation between visfatin and free thyroxin. Conclusion: Our results are consistent with several studies, which confirmed association between AIT and adipocytokines. This is a continuation of the study with the same focus from 2019. The number of examined individuals increased to more than one and a half times.

Keywords:

Adiponectin – type 2 diabetes mellitus – adipocytokines – autoimmune thyroiditis – resistin – visfatin

Sources

1. Sotak Š, Schroner Z, Lazúrová I et al. The association between three adipocytokines (adiponectin, resistin and visfatin) and thyroid status in patients with type 2 diabetes mellitus and autoimmune thyroiditis. Physiol Res. 2021; 70(6): 865–874. Dostupné z DOI: <http://dx.doi.org/10.33549/physiolres.934701>.

2. Sotak Š, Schroner Z, Lazúrová I et al. Adipocytokíny ako možné etiopatogenetické mechanizmy vedúce k vyššiemu výskytu autoimunitnej tyroiditídy u pacientov s diabetes mellitus 2. typu. Diab Obez 2019; 19(38): 103–109.

3. Soriguer F, Valdes S, Sonsoles M et al. Thyroid hormone levels predict the change in body weight: a prospective study. Eur J Clin Invest 2011; 41(11): 1202–1209. Dostupné z DOI: <http://dx.doi.org/10.1111/j.1365–2362.2011.02526.x>.

4. Ozcelik F, Yuksel C, Arslan E et al. Relationship between visceral adipose tissue and adiponectin, inflammatory markers and thyroid hormones in obese males with hepatosteatosis and insulin resistance. Arch Med Res 2013; 44(4): 273–280. Dostupné z DOI: <http://dx.doi.org/10.1016/j.arcmed.2013.04.001>.

5. Yuan T, Zhao W, Sun Q et al. Association between four adipokines and insulin sensitivity in patients with obesity, type 1 or type 2 diabetes mellitus, and in the general Chinese population. Chin Med J (Engl) 2010; 123(15): 2018–2022.

6. Nagaev I, Smith U. Insulin resistance and type 2 diabetes are not related to resistin expression in human fat cells or skeletal muscle. Biochem Biophys Res Commun 2001; 285(2): 561–564. Dostupné z DOI: <http://dx.doi.org/10.1006/bbrc.2001.5173>.

7. Muse ED, Lam TKT, Scherer PE et al. Hypothalamic resistin induces hepatic insulin resistance. J Clin Invest. 2007; 117(6): 1670–1678. Dostupné z DOI: <http://dx.doi.org/10.1172/JCI30440>.

8. Mojiminiyi OA, Abdella NA. Associations of resistin with inflammation and insulin resistance in patients with type 2 diabetes mellitus. Scand J Clin Lab Invest 2007; 67(2): 215–225. Dostupné z DOI: <http://dx.doi.org/10.1080/00365510601032532>.

9. Heilbronn LK, Rood J, Janderova L et al. Relationship between serum resistin concentrations and insulin resistance in nonobese, obese, and obese diabetic subjects. J Clin Endocrinol Metab 2004; 89(4): 1844–1848. Dostupné z DOI: <http://dx.doi.org/10.1210/jc.2003–031410>.

10. Fujinami A, Obayashi H, Ohta K et al. Enzyme-linked immunorbent assay for circulating human resistin: resistin concentrations in normal subjects and patients with type 2 diabetes. Clinica Chimica Acta 2004; 339(1–2): 57–63. Dostupné z DOI: <http://dx.doi.org/10.1016/j.cccn.2003.09.009>.

11. Degawa-Yamauchi M, Bovenkerk JE, Juliar BE et al. Serum resistin (FIZZ3) protein is increased in obese humans. J Clin Endocrinol Metab 2003; 88(11): 5452–5455. Dostupné z DOI: <http://dx.doi.org/10.1210/jc.2002–021808>.

12. Oweck M, Nikisch E, Miczke A et al. Serum resistin concentrations are associated with HbA1c in obese non-diabetics, but not in obese diabetics: A cross-sectional human study. Neuro Endocrinol Lett 2011; 32(3): 349–353.

13. Bajnok L, Seres I, Varga Z et al. Relationship of serum resistin level to traits of metabolic syndrome and serum paraoxonase 1 activity in a population with a broad range of body mass index. Exp Clin Endocrinol Diabetes 2008; 116(10): 592–599. Dostupné z DOI: <http://dx.dpo.org/10.1055/s-2008–1065350>.

14. Iglesias P, Fidalgo PA, Codoceo R et al. Serum concentrations of adipocytokines in patients with hyperthyroidism and hypothyroidism before and after control of thyroid function. Clin Endocrinol (Oxf). 2003; 59(5): 621–629. Dostupné z DOI: <http://doi: 10.1046/j.1365–2265.2003.01897.x>.

15. Santini F, Marsili A, Mammoli C et al. Serum concentrations of adiponectin and leptin in patients with thyroid dysfunctions. J Endocrinol Invest 2004; 27(2): RC5-RC7. Dostupné z DOI: <http://doi:10.1007/BF03346252>.

16. Altinova AE, Törüner FB, Aktürk M et al. Adiponectin levels and cardiovascular risk factors in hypothyroidism and hyperthyroidism. Clin Endocrinol 2006; 65(4): 530–535. Dostupné z DOI: <http://doi: 10.1111/j.1365–2265.2006.02628.x>.

17. Iglesias P, Díez JJ. Influence of thyroid dysfunction on serum concentrations of adipocytokines. Cytokine 2007; 40(2): 61–70. Dostupné z DOI: <http://doi: 10.1016/j.cyto.2007.10.001>.

18. Siemińska L, Wojciechowska C, Kos-Kudła B et al. Serum concentrations of leptin, adiponectin, and interleukin-6 in postmenopausal women with Hashimoto‘s thyroiditis. Endokrynol Pol 2010; 61(1): 112–116.

19. Kaplan O, Uzum AK, Aral H et al. Unchanged serum adipokine concentrations in the setting of short-term thyroidectomy-induced hypothyroidism. Endocr Pract 2012; 18(6): 887–893. Dostupné z DOI: <http://doi: 10.4158/EP12001>.

20. Yldiz BO, Aksoy DY, Harmanci A et al. Effects of l-thyroxine therapy on circulating leptin and adiponectin levels in subclinical hypothyroidism: a prospective study. Arch Med Res 2013; 44(4): 317–320. Dostupné z DOI: <http://doi: 10.1016/j.arcmed.2013.04.010>.

21. Caixàs A, Tirado R, Vendrell J et al. Plasma visfatin concentrations increase in both hyper and hypothyroid subjects after normalization of thyroid function and are not related to insulin resistance, anthropometric or inflammatory parameters. Clin Endocrinol (Oxf) 2009; 71(5): 733–738. Dostupné z DOI: <http://doi: 10.1111/j.1365–2265.2009.03546.x>.

22. Han J, Zhang T, Xiao W et al. Up-regulation of visfatin expression in subjects with hyperthyroidism and hypothyroidism is partially relevant to a nonlinear regulation mechanism between visfatin and tri-iodothyronine with various concentrations. Chin Med J 2012; 125(5): 874–881.

23. Guzel S, Seven A, Guzel EC et al. Visfatin, leptin, and TNF-α: Interrelated adipokines in insulin-resistant clinical and subclinical hypothyroidism. Endocr Res 2013; 38(3): 183–193. Dostupné z DOI: <http://doi 10.3109/07435800.2012.760588>.

24. Ozkaya M, Sahin M, Cakal E et al. Visfatin plasma concentrations in patients with hyperthyroidism and hypothyroidism before and after control of thyroid function. J Endocrinol Investig 2009; 32(2): 435–439. Dostupné z DOI: <http://doi 10.1007/BF03346482>.

25. Farazandeh MM, Shabani S, Hoghooghi RL et al. Relationship between visfatin hormone and thyroid dysfunction in patients with hyperthyroidism and hypothyroidism. Kowsar Med J 2011; 16(3): 181–184.

26. Yayali GF, Turgut S, Akin F et al. Visfatin levels in subclinical hypothyroidism. Int J Pept Res Ther 2016; 22: 11–14.

27. Fukuhara A, Matsuda M, Nishizawa M et al. Erratum (Retracted article): visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science 2007; 318(5850): 565. Dostupné z DOI: <http://doi 10.1126/science.318.5850.565b>.